Covid-19 | Bharat Biotech's nasal booster gets approval for trials

Covaxin maker Bharat Biotech has received Drugs Controller General of India's permission to conduct Phase 3 trials for its nasal booster dose for novel coronavirus. 

The trials will be conducted at 9 locations in the country. 

Bharat Biotech has said that the intranasal booster dose will meant for people who have received both shots of Covaxin and it will be easier to administer during mass vaccination drives. 

According to the vaccine maker, the nasal dose, BBV154, stimulates immune responses at the the site of infection -- the nose -- and is very effective in blocking infection and transmission of Covid-19.

Also watch: NeoCov Covid variant: Have Chinese scientists just found the deadliest of all strains?

The approval comes a day after Bharat Biotech's Covaxin and Serum Institute of India's Covishield were cleared for sale in hospitals and clinics.